CoLucid Pharmaceuticals, Inc. 4
4 · CoLucid Pharmaceuticals, Inc. · Filed Jan 5, 2017
Insider Transaction Report
Form 4
Mathers Thomas P.
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2017-01-05−3,755→ 105,147 total→ Common Stock (3,755 underlying) - Sale
Common Stock
2017-01-05$34.25/sh−802$27,465→ 257,219 total - Sale
Common Stock
2017-01-05$34.86/sh−200$6,972→ 257,019 total - Sale
Common Stock
2017-01-05$35.60/sh−500$17,800→ 256,519 total - Exercise/Conversion
Common Stock
2017-01-05+3,755→ 258,021 total
Footnotes (5)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of CoLucid Pharmaceuticals, Inc. common stock.
- [F2]Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Mathers on August 19, 2016. The purpose of the plan was to sell shares of common stock in order to pay the taxes related to the settlement of the RSUs.
- [F3]Represents the sale of 802 shares in multiple transactions, ranging in price from $33.45 to $34.40 per share, resulting in a weighted average sale price of $34.2462. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- [F4]Represents the sale of 200 shares in multiple transactions, ranging in price from $34.50 to $35.225 per share, resulting in a weighted average sale price of $34.8625. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- [F5]On May 5, 2015, the reporting person received 360,508 RSUs. Those RSUs vest as follows: 50% of the RSUs vested on November 5, 2015; 12.5% of the RSUs vested on May 5, 2016; and the remaining RSUs vest in a series of 36 successive equal monthly installments upon completion of each additional month of service.